论文部分内容阅读
宫颈癌是妇科常见恶性肿瘤，其早期诊断和预后判断已成为宫颈癌研究的热点。目前观点一致认为，联合检测多种肿瘤标志物能提高宫颈癌诊断的准确性，同时也有助于临床治疗中的疗效评价及预后判断。近年来，血清鳞状细胞癌抗原（ SCCA）、铁蛋白（ SF）和癌胚抗原（ CEA）被发现对宫颈癌有更高的预测和监测价值。虽然多种肿瘤标志物联合检测目前尚无最佳组合，但血清SCCA联合SF和CEA检测在宫颈癌的临床应用，可为宫颈癌诊疗提供新思路。“,”Cervical cancer is a common gynecologic malignant tumor .The early diagnosis and prognosis evaluation have become a hot research focus of cervical cancer .It is now agreed that Joint detection of multi-tumor markers can improve the cervical cancer diagnosis accuracy in the early stage and it can also help the evaluation of the clinical treatment effect and prognosis judgment .Recently,joint detection of squamous cell carcinoma antigen(SCCA),serum ferritin(SF) and carcino-embryonic antigen(CEA) are found to have a higher predictive and monitoring value for cervical cancer .Although there is no optimal combination of the multiple tumor markers,the clinical application of SCCA,SF and CEA combined detection on cervical cancer may provide a new way for the diagnosis and treatment of cervical cancer.